Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Conditions
Interventions
Encorafenib
Binimetinib
+4 more
Locations
418
United States
Mayo Clinic Hospital
Phoenix, Arizona, United States
Mayo Clinic
Phoenix, Arizona, United States
Mayo Clinic
Scottsdale, Arizona, United States
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California, United States
Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc.
Fountain Valley, California, United States
Keck Hospital of USC - Norris Healthcare Center (HC3)
Los Angeles, California, United States
Start Date
October 13, 2016
Primary Completion Date
February 11, 2019
Completion Date
November 10, 2022
Last Updated
December 21, 2023
Lead Sponsor
Pfizer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions